Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eytan M Stein

Showing results (1-10 of 147) with videos related to

Pageof 15
Sort By:
Clinical Advances in Hematology & Oncology : H&O|September 8, 2021
IDH inhibitors in acute myeloid leukemia and myelodysplastic syndromeEytan M Stein
Blood|January 12, 2023
IDH2 inhibition in AMLEytan M Stein
Journal of Oncology Practice|August 11, 2017
Minimal Residual Disease in Acute Myeloid Leukemia: Prognostication and PitfallsEytan M Stein
Best Practice & Research. Clinical Haematology|November 23, 2015
IDH2 inhibition in AML: Finally progress?Eytan M Stein
Future Oncology (London, England)|December 16, 2017
Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemiaEytan M Stein
The Lancet. Oncology|June 4, 2018
FLT3 inhibitors for relapsed or refractory acute myeloid leukaemiaEytan M Stein
Haematologica|April 15, 2021
The promised landEytan M Stein
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2015
Molecular Pathways: IDH2 Mutations-Co-opting Cellular Metabolism for Malignant TransformationEytan M Stein
Hematology. American Society of Hematology. Education Program|December 6, 2015
Molecularly targeted therapies for acute myeloid leukemiaEytan M Stein
Haematologica|August 2, 2019
Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?Brian Ball, Eytan M Stein
Pageof 15

Showing results (1-10 of 147) with videos related to

Sort By:
Pageof 15
Clinical Advances in Hematology & Oncology : H&O|September 8, 2021
IDH inhibitors in acute myeloid leukemia and myelodysplastic syndromeEytan M Stein
Blood|January 12, 2023
IDH2 inhibition in AMLEytan M Stein
Journal of Oncology Practice|August 11, 2017
Minimal Residual Disease in Acute Myeloid Leukemia: Prognostication and PitfallsEytan M Stein
Best Practice & Research. Clinical Haematology|November 23, 2015
IDH2 inhibition in AML: Finally progress?Eytan M Stein
Future Oncology (London, England)|December 16, 2017
Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemiaEytan M Stein
The Lancet. Oncology|June 4, 2018
FLT3 inhibitors for relapsed or refractory acute myeloid leukaemiaEytan M Stein
Haematologica|April 15, 2021
The promised landEytan M Stein
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2015
Molecular Pathways: IDH2 Mutations-Co-opting Cellular Metabolism for Malignant TransformationEytan M Stein
Hematology. American Society of Hematology. Education Program|December 6, 2015
Molecularly targeted therapies for acute myeloid leukemiaEytan M Stein
Haematologica|August 2, 2019
Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?Brian Ball, Eytan M Stein
Pageof 15